Upadacitinib

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more.

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.

In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.

The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.

Physician understanding about the safety and efficacy of Janus kinase inhibitors for patients with rheumatoid arthritis has evolved with real-world and clinical trial data.

Nearly half of patients with giant cell arteritis who received upadacitinib while tapering steroids achieved remission from weeks 12 through 52 in a phase 3 trial, according to a press release from AbbVie.

Adults and adolescents with moderate to severe atopic dermatitis treated with upadacitinib reported year-long improvements in skin symptoms, mental health and quality of life, according to a study.

Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.